Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Comparative Clinical Study of the Dietary Supplement "Gepaktiv" (International Name: Phenomenon) in Comparison With Ursodeoxycholic Acid (UDCA) and Ademetionine in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) and Hepatomegaly

NCT07068191 is registered in ClinicalTrials.gov with Phenomen Pharma as lead sponsor.

NCT NCT07068191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07068191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Comparative Clinical Study of the Dietary Supplement "Gepaktiv" (International Name: Phenomenon) in Comparison With Ursodeoxycholic Acid (UDCA) and Ademetionine in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) and Hepatomegaly
Lead sponsor
Phenomen Pharma
Phase
Not applicable
Overall status
Recruiting
Start date
June 19, 2025
Completion date
August 31, 2025
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fatty liver, fatty liver disease, fatty liver, alcoholic, fatty liver, nonalcoholic, hepatomegaly, metabolic dysfunction-associated fatty liver disease (mafld), nonalcoholic fatty liver (nafl), nonalcoholic fatty liver disease (nafld)